FDA grants 12-year exclusivity to Flublok; Emergent BioSolutions' Ebola candidate enters Ph I;

> The FDA granted 12-year exclusivity to Protein Sciences' Flublok, which means no product similar to Flublok can be approved by the FDA before Jan. 16, 2025. Release

> Emergent BioSolutions' ($EBS) investigational Ebola vaccine, produced using ProBioGen's platform, has entered clinical trials at Oxford University in the U.K. Release

> Griffith University's Institute for Glycomics has developed a combination vaccine that may beat Streptococcus A infections. Human trials may begin as early as 2016. More

> Soligenix announced data demonstrating a heat-stable formulation of an HPV vaccine. Release

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.